LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies
Updated: Jan 7
Rare disease and gene therapy industry veterans Steven Altschuler, M.D., R. Nolan Townsend, and Jay Barth, M.D., team up with gene therapy pioneer Ronald Crystal, M.D., to launch fully integrated gene therapy company.
Financing led, structured and syndicated by Longitude Capital and Omega Funds.
Comprehensive pipeline includes three clinical-stage gene therapy programs in monogenic diseases and up to 15 potential additional AAV gene therapy programs in monogenic and acquired diseases primarily developed at Weill Cornell Medicine.